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ABSTRACT 
 
Background: Evidence suggests cannabis-induced psychotic-like 
experiences may be a marker of psychosis proneness. The effect of such 
experiences on cannabis use has not systematically been examined. 
Methods: We undertook a mixed-methods online survey of 1231 cannabis 
users (including 926 continued users) using the Cannabis Experiences 
Questionnaire. We examined the effect of psychotic-like and pleasurable 
experiences on cessation of cannabis and intention to quit. Socio-
demographic variables, cannabis use parameters, and substance misuse 
history were included as covariates. Free-text data explored subjective 
reasons for changes in use.  
Results: Cessation of cannabis use was associated with greater psychotic-
like experiences (p<0.001, Exp(B) 1.262, 95%CI: 1.179-1.351) whilst 
continued cannabis users were more likely to report pleasurable experiences 
(p<0.001, Exp(B) 0.717, 95%CI 0.662-0.776). Intention to quit cannabis in 
continued users was associated with greater psychotic-like experiences 
(p<0.003, Exp(B) 1.131, 95%CI: 1.044-1.225) whilst intention to not quit was 
significantly associated with increased pleasurable experiences (p<0.015, 
Exp(B) 0.892, 95%CI 0.814-0.978). Whereas former users clearly ascribed 
cessation to negative experiences; continued users who expressed intention 
to quit less readily ascribed the intention to negative experiences.   
Conclusions: Elucidation of psychotic-like experiences may form the basis of 
a therapeutic intervention for those who wish to quit. Cessation in those with 
cannabis-induced psychotomimetic experiences may offset the risk for 
development of psychotic disorder, in this higher risk group.  
 
!MANUSCRIPT 
 
Introduction: 
 
Cannabis use is widespread with an estimated 125-203 million users 
worldwide(Degenhardt & Hall 2012). Initiation of cannabis use has been 
associated with increased risk of onset of psychotic symptoms whilst 
continued use is associated with persistence of such symptoms(Kuepper et 
al. 2011) and onset of psychotic disorder(Moore et al. 2007; Marconi et al. 
2016). This is consistent with meta-analytic and independent evidence that 
continued cannabis use is associated with greater risk of relapse in those with 
pre-existing psychotic disorder(Schoeler et al. 2016a, 2016b) and that this 
association is more likely than not to reflect a causal effect of continued 
cannabis use on outcome(Schoeler et al. 2016c). This convergence of 
evidence suggests that persistence of use is a key determinant of the effect of 
cannabis use on outcome both in healthy and unwell cannabis users. 
Therefore, understanding what factors influence persistence of use or indeed 
trigger cessation or a desire to quit is critical to developing effective 
interventions that may help limit harm from cannabis use.  
 
Work to date has focused on established social constructs as predictors of 
cessation and has demonstrated that increasing age and maturity are 
associated with cessation (the “maturing out” hypothesis)(Kandel & Logan 
1984) whilst social context, poor health and prior illicit drug use are associated 
with ongoing use(Kandel & Raveis 1989). Other work has also pointed toward 
peer involvement and school problems(van den Bree et al. 2005) as well as 
!psychological dependence and drug myths(Little et al. 2013) as associated 
with persistence of cannabis use in young people.  
 
Experiences during the transient intoxication state immediately following 
cannabis use, which can constitute both pleasurable and undesirable 
experiences have also been examined to determine their effect on 
subsequent use. Both early and persisting pleasurable experiences have 
been shown to be associated with heavier use and dependence(Le Strat et al. 
2009; Scherrer et al. 2009). However evidence is equivocal about the effect of 
undesirable experiences on subsequent cannabis use patterns, with studies 
showing both association with decreased(Lyons et al. 1997; Zeiger et al. 
2010) as well as heavier or problematic use(Grant et al. 2005; Scherrer et al. 
2009). This may reflect the fact that existing literature examining the 
association between undesirable experiences during cannabis use and 
subsequent pattern of use have focused on a wide array of undesirable 
effects, including drowsiness, confusion and nausea rather than on effects 
such as ‘psychotic-like experiences’, which arguably are perhaps the most 
distressing and frightening experiences in someone expecting to enjoy a 
relaxing effect. Unlike the relatively rare occurrence of psychotic disorder 
associated with cannabis use(Moore et al. 2007; Marconi et al. 2016) 
psychotic-like experiences, such as paranoia, hallucinations or dysphoria, are 
not uncommon, reported by up to 15% of cannabis users in a community 
sample(Thomas 1996). Whether the occurrence of undesirable experiences 
such as psychotic-like experiences in particular whilst using cannabis has an 
influence on subsequent cannabis use behaviour is therefore an important 
question to examine. However, to our knowledge this has not been 
systematically examined to date.  
! 
Employing a well-validated(Barkus et al. 2006; Bianconi et al. 2016; Quinn et 
al. 2016) self-report questionnaire that has been used to record subjective 
experiences associated with cannabis use, previous and more recent 
exploratory factor analyses have shown that the immediate transient 
experiences associated with cannabis use cluster into ‘paranoid-dysphoric 
experiences’ and ‘pleasurable experiences’(Barkus et al. 2006; Quinn et al. 
2016). Hence, in the present study we sought to investigate whether 
experiences during cannabis use (both psychotomimetic and pleasurable) are 
associated with cessation of use or a future intention to quit in a non-clinical 
sample.  We hypothesised that (i) psychotic-like experiences would be 
associated with cessation of cannabis use and a desire to quit, whereas (ii) 
pleasurable experiences would conversely be associated with continuation of 
cannabis use and a desire to continue. Furthermore, we triangulated analysis 
using a mixed-methods approach to qualitatively explore subjective reasons 
reported by users as being linked to continued use. We inductively coded 
qualitative data independently of the quantitative analysis in order to allow 
participants’ own views relating to changes in their patterns of use 
(continuation, escalation, more ‘measured’ use or complete cessation) to their 
reported cannabis experiences, to emerge. 
 
Methods: 
Ethical approval was obtained from the King’s College, London Research 
Ethics Committee (REMAS). We have followed the STrengthening the 
Reporting of OBservational studies in Epidemiology (STROBE) guidelines for 
reporting of cross-sectional studies(von Elm et al. 2007). 
 
!A web-based modified version of the Cannabis Experiences Questionnaire 
(CEQ) was administered to an internet sample.  
 
Sample selection: 
Participants were recruited through advertising on the study recruitment 
pages at King's College London, the London Cannabis Club, cannabis 
advocacy sites such as CLEARUK and social media including Facebook, 
Twitter and Tumblr. An internet domain name for the survey was registered 
and advertised (www.thecannabissurvey.com). Adults aged 18 years and 
above who had previously used cannabis were invited to complete the survey. 
A small-scale raffle (£10-£50 Amazon voucher for three participants on 
completion) was offered as an incentive. The survey ran over a 10-month 
period from December 2015 until September 2016. We aimed for a sample 
size of 1000 as this would be the largest population-derived sample assessed 
with the CEQ to date(Barkus et al. 2006; Bianconi et al. 2016; Quinn et al. 
2016), 
 
Measures: 
 
The CEQ was developed to investigate participants’ self-reports of 
experiences with cannabis(Barkus et al. 2006). It has demonstrated validity 
and reliability having been administered in student, online, non-clinical and 
clinical cohorts(Barkus et al. 2006; Barkus & Lewis 2008; Bianconi et al. 2016; 
Quinn et al. 2016). We have used the modified version previously in a clinical 
sample via face to face and telephone interview with demonstrable 
acceptability in collecting cannabis use data. We used a modified version 
previously administered in our centre (Di Forti et al. 2009, 2012, Schoeler et 
!al. 2016b, 2016c). For brevity, and in order to facilitate data collection, the 
survey restricted itself to nine intoxication experiences and did not collect data 
on the after effects of cannabis use.  Prior to this we had not tested the 
modified version online, although other groups have administered alternative 
versions of the CEQ to electronic and online sample and reported acceptable 
psychometric properties(Barkus & Lewis 2008; Quinn et al. 2016).  
 
Predictor variables: 
The administered survey included six items focusing on psychotic-like 
experiences (fearfulness, feeling of going crazy, feeling nervy, 
suspiciousness, seeing visions and hearing voices) and three items on 
pleasurable effects (being full of plans, feeling happy, being able to 
understand the world better). These were scored on a Likert scale assessing 
the frequency of ever having experienced the specified effect using 
established anchor points (1 rarely or never, 2 from time to time, 3 sometimes, 
4 more often than not, 5 almost always).  
 
Outcome variables: 
Outcome variables were collected as dichotomous ‘yes/no’ answers (i) for all 
those who had ever used cannabis whether they continued to use; and (ii) in a 
further question restricted to those who continued to use cannabis, whether 
they intended to quit in the future.  
 
Covariate variables: 
Socio-demographic variables collected were: age, sex (male, female) and 
occupational status. Additional parameters of cannabis, alcohol and other 
drug use collected included:  Age of first cannabis use, Frequency of cannabis 
!use (every day, a few times a week, a few times each month, a few times 
each year, only once or twice), other substance misuse history for tobacco, 
alcohol, cocaine, ecstasy and non-prescribed medication (used regularly, 
used frequently, used less than 5 times, never used). History of lifetime 
contact with mental health services or requiring treatment was collected as a 
dichotomous (yes/no) variable.  
 
Qualitative data: 
Free-text fields were used for the collection of qualitative data with specific 
questions on: reasons for initiation, continuation and/or cessation of cannabis 
use, thoughts about future cessation or continuation of use, subjective 
reasons given for changes in patterns of use. 
 
Statistical Analysis 
CEQ scores for psychotic-like experiences and pleasurable experiences were 
calculated by simple summation of Likert scales as followed 
previously.(Barkus et al. 2006) The range of total possible scores for 
psychotic like experiences was 6-30, whereas pleasurable experiences score 
ranged from 3-15. Since psychotic and pleasurable experiences represent 
underlying continua, summed scores were treated as a continuous variable. 
 
Descriptive statistics for the predictor, covariate and outcome variables were 
estimated as means and standard deviations (SD) for continuous variables 
(psychotic-like experiences score, pleasurable experiences score, age, age of 
first use of cannabis), and as frequencies and percentages for all other 
variables (sex, occupation, frequency of cannabis use, any prior mental health 
!contact, history of use of: alcohol, tobacco, non-prescription medications, 
cocaine and ecstasy).  
 
First exploratory analyses, including t-tests for continuous variables and chi-
square test for categorical variables were undertaken to compare the 
cessation versus continuation user groups and further within continued users 
to compare those with future intention to quit versus those with no intention to 
quit. Multivariable binary logistic regression analyses were undertaken to 
examine the association between psychotic-like experiences and pleasurable 
experiences as predictors with cessation/continuation and future intention to 
quit/no intention to quit as outcomes. In order to account for potential 
confounders, the following measures were included in these models as 
covariates: age, sex, occupation, age of first use of cannabis, frequency of 
cannabis use, past drug history and contact with mental health services. All 
predictor and covariate variables were entered into the regression model 
simultaneously. Checking Variation Inflation Factor confirmed there was no 
multicollinearity amongst predictor and covariate variables at a conservative 
threshold (VIF<2.5 in all instances).   
 
Missing data: Fisher’s 2x2 exact test was undertaken to see if there was a 
significant effect of missing data between groups (continued vs. discontinued 
and future intention to quit vs. no intention to quit) for all covariates (age, sex, 
occupation, mental health contact, age of first use, frequency of first use, 
alcohol, tobacco, non prescribed medication, cocaine and ecstasy history) 
(see Table 1). There were no significant differences in rates of missing data 
between groups for continued users who had intention to quit vs. no intention 
to quit. There were furthermore no significant differences for rates of missing 
!data for continued vs discontinued users for all covariates except for 
occupation (4.6% vs 1.0%, p=0.03) and frequency of use (3.0% vs 7.2%, 
p<0.01), however even in these two instances the overall differences in 
proportions of missing data between groups was ajudged to be small and not 
evidence systematic bias in missing data. Consequently we undertook a 
complete case analysis, (where there were no missing data for all covariates 
specified above) to account for missing data (see supplementary material) in 
preference to imputation methods.  
 
Sensitivity analyses: we re-ran the statistical analyses with the complete case 
data excluding participants with a history of psychotic or manic illness. 
Furthermore to ensure that those who reported discontinuation would be 
objectively considered to have ceased use we re-ran the analysis with 
discontinued users restricted to the group who had reported last use of 
cannabis to be at least six months previously. To ensure any relationships 
were not accounted for by infrequent or experimental users we checked 
whether the relationship between experiences and discontinuation / future 
discontinuation survived across differing levels of use by running the logistic 
regression with data split by frequency of use. In this case frequency of use 
was removed as a covariate from logistic regression models.  
 
Statistical Analysis was undertaken in SPSS version 20.  
 
Qualitative Analysis 
Open-ended questionnaire responses to questions on reasons stated for 
discontinued cannabis use (experiences), descriptions of negative 
experiences, and stated reasons for changes in patterns of use over time 
!were transcribed, collated and inductively coded by an independent 
researcher who had not been involved in the design of the quantitative survey 
(CN). Following a thematic approach(Braun & Clarke 2006), no a priori coding 
structure was applied, but themes were allowed to ‘emerge’ naturally from the 
data, and were grouped in meaningful ways to assist with interpretation of the 
data. Analysis was discussed and verified at regular team meetings. This 
analysis was undertaken independently but in parallel with the quantitative 
analysis. 
 
Results: 
 
Demographics: 
In total, 1425 participants responded to the survey. Five participants were 
excluded due to being under 18. Of the remaining data was available for 1231 
participants who had ever used cannabis (see Fig 1). Complete case data 
was available for 940 participants. Summary demographic and predictor, 
outcome and covariate data are reported in Table 1.  845/1231 (68.6%) were 
male, whereas 375/1231 (30.5%) were female. Age ranged from 18-77 years 
(mean 29.5, median 26, standard deviation 10.3). 469 (38.1%) of the 
respondents reported previous mental health contact. While this was not 
quantified based on free-text information this appeared to be mostly related to 
anxiety, depression or stressful experiences and involved treatment within the 
primary care setting or by counseling. 25/1231 (2.0%) participants included in 
the analysis referred to a diagnosis of psychotic or manic illness.  
 
Although we did not routinely ask for country, 494/531 (93.0%) of those who 
agreed to a follow-up study gave their place of residence in the United 
!Kingdom, with 23/531 (4.3%) responding from Sweden, although there were 
also a few responses from the USA, Brazil, Mauritius, Greece and Zimbabwe. 
 
Cannabis Use: 
926/1231 (75.2%) continued to use the substance. 167/907 (18.4%) of 
continued users agreed that they would like to stop in the future. In all users 
pleasurable experiences were more frequently reported than psychotic 
experiences. Age of first cannabis use ranged from 7-55 years (mean 16.7, 
median 16, SD 3.7).  
 
Cannabis experiences: 
Pleasurable experiences exceeded psychotic-like experiences. 915/1123 
(81.4%) of respondents in this sample reported that they experienced 
happiness either most or all of the times they used cannabis, whilst 66/1119 
(5.9%) of respondents endorsed ‘feeling nervy’, the most common dysphoric 
experience. A considerable proportion of cannabis users had ever 
experienced psychotic or dysphoric experiences when using cannabis: feeling 
suspicious: 524/1117 (46.9%); feeling nervy: 491/1119 (43.9%); feeling 
fearful: 302/1123 (27.1%); seeing visions: 187/1118 (16.7%); feeling like 
going crazy or mad: 145/1121 (12.9%); and hearing voices: 100/1117 (9.0%).  
 
Cannabis Experiences cessation vs. continuation 
Psychotic-like experiences and pleasurable experiences scores by ceased 
and continued users are shown in Table 2a. Those who had ceased reported 
greater frequency of experiencing psychotic-like experiences (t=7.05, 
p<0.001) whereas continued cannabis users were significantly more likely to 
report pleasurable experiences than those who had ceased (t=-16.67, 
!p<0.001). These findings remained when the complete data-set was analysed 
and further when those with a history of psychotic or manic illness were 
excluded(see supplementary data).  
 
Results from a logistic regression analysis are summarized in Table 3a. 
Cessation of cannabis use was significantly associated with psychotic-like 
experiences (higher score predicts cessation), pleasurable experiences (lower 
score predicted cessation), age (older age predicted cessation), sex (being 
female predicted cessation) and frequency of cannabis use (less frequent use 
predicted cessation). Tobacco use was also borderline significant (p=0.51), 
indicating more frequent tobacco use predicted continuation.  
 
Cannabis Experiences in continued users: No intention to quit vs. Future 
intention to quit. 
Within continued cannabis users, future intention to quit was significantly 
associated with greater psychotic-like experiences (t=3.95, p<0.001) and 
lower pleasurable experiences (t=-2.37, p=0.017) (see Table 2b). These 
findings were replicated when the complete data-set was analysed (see 
supplementary data). Logistic regression (Table 3b) analyses suggested that 
future intention to quit was significantly associated with psychotic-like 
experiences (higher score predicted future intention to quit) pleasurable 
experiences (lower score predicted future intention to quit), age (lower age 
predicted future intention to quit), sex (being females predicted future intention 
to quit) and history of tobacco use (more frequent use predicted future 
intention to quit). History of non-prescribed medication use was also 
borderline significant (p=0.49, less frequent use predicted future to quit). 
 
!Sensitivity analyses: 
On sensitivity analyses, when the complete data-set was analysed (i) with 
those with psychosis or manic illness excluded and (ii) restricted to 
discontinued users who reported last use of cannabis more than six months 
previously, psychotic-like experiences and pleasurable experiences 
significantly predicted cessation in the same direction. The same relationship 
between psychotic like experiences and pleasurable experiences remained 
statistically significant when restricted to daily users (see supplementary 
data). 
 
Qualitative Analysis 
In total 1107 unique participants provided qualitative feedback. 312 unique 
‘open’ codes were inductively derived from the data. Qualitative coding 
broadly identified the dominant themes of significant negative experiences as 
impacting on continued cannabis use (see supplementary data on coding 
‘Why did you stop/Negative psychological symptoms’). Within coding of 
responses to the question ‘why have patterns of use changed?’, 121 codes 
were broadly categorised into individual, interpersonal, community, 
organisational and policy level themes. Additional themes related specifically 
to constituents of cannabis, the micro-context of use and the concept of 
‘maturation’. Drawing on subjective participant perspectives, negative 
experiences were linked to the type of cannabis used, particularly strong 
types of cannabis (skunk) and synthetic cannabis. Participants made clear 
links between their negative experiences, their cannabis use, and their future 
intentions, such that negative experiences were considered to be somewhat 
protective of future cannabis use (see supplementary data on coding ‘Why 
have patterns of use changed/negative effects’). Indeed, our coding clusters 
!particularly around individual level factors, suggesting that experience at the 
individual level of perception and interpretation is critical in informing 
continued patterns of cannabis use.  Those who did not report severe 
negative experiences also discussed future intention to discontinue cannabis 
use, but intentions in these cases were framed around ‘growing older’, moving 
away from cannabis use, and discontinued use to match life events (notably 
getting married, starting a family, starting full time employment) (see 
supplementary data on coding ‘would you like to stop using cannabis one 
day/maturing out). 
 
Discussion: 
 
We investigated the impact of desirable and undesirable transient subjective 
experiences such as ‘pleasurable’ and ‘psychotic-like experiences’ 
respectively on subsequent cannabis use behaviour as indexed by cessation 
or continuation of cannabis use as well as future intention to quit in those who 
continue to use cannabis in a large internet-based participant survey.  Our 
results from a combination of quantitative and qualitative analyses converge 
to demonstrate that psychotic-like experiences are strongly associated with 
both cannabis cessation and future intention to quit. These results survived 
controlling for potential confounding factors that may also be associated with 
these outcomes and is particularly evident in those who use cannabis most 
frequently. 
 
Qualitative data further support these relationships such that those who have 
discontinued cannabis are more ready to clearly ascribe this to negative 
experiences. However, those who intend to stop using cannabis in the future 
!do not necessarily ascribe intention to stop to anticipated negative 
experiences. Together, the significant association between negative 
subjective experiences and cessation may suggest that the elucidation of 
such experiences may form the basis of a therapeutic intervention for those 
who express a desire to quit. 
   
Conversely, this study clearly demonstrates that pleasurable experiences are 
associated with continued use and lack of intention to quit. This is in line with 
previous studies in this area(Grant et al. 2005; Scherrer et al. 2009). 
Cannabis is thus evidently experienced as a pleasurable drug and this would 
appear to account for its ongoing and continued use. 
 
To date there is no consensus in the literature as to whether adverse 
experiences are associated with reduced or heavier use(Lyons et al. 1997; 
Grant et al. 2005; Scherrer et al. 2009; Zeiger et al. 2010). To our knowledge 
no prior studies have systematically looked to examine specifically the effect 
of cannabis induced psychotic-like experiences on cannabis cessation. Two 
studies have however reported on incidental findings which support the 
direction of our findings. Whilst validating the Cannabis Experiences 
Questionnaire Stirling et al noted continued cannabis users to report more 
positive and less negative experiences than past users(n=185)(Stirling et al. 
2008). Whilst testing whether psychotic-like experiences are a marker of 
psychosis proneness, Mason and colleagues noted that a greater acute 
psychotomimetic state effect was associated with less frequent cannabis use 
(n=140)(Mason et al. 2009).  Our data extends previous work by clearly 
indicating that psychotic-like experiences are associated with cessation and 
are attributed as one of the main drivers underlying cessation by those who 
!have successfully stopped. Furthermore, by demonstrating an association 
between psychotic-like experiences and a future intention to cease, which is 
not consciously recognised as such by continued users, these results also 
suggest a potential intervention target. Given that our data show psychotic-
like experiences in both continued and discontinued users, this may indicate 
that as pleasurable experiences are predominant they may override 
occasional negative experiences, even if the experience is severe. However 
the results of this study may have implications beyond this. 
 
A central argument against the relationship between cannabis use and 
psychosis risk has been that whereas cannabis prevalence and potency has 
increased over the last four decades there has been not been a 
corresponding increase in population level incidence of psychotic 
disorders(Frisher et al. 2009) as would be expected were cannabis use to be 
causally linked to psychosis risk. This has been argued to critically weaken 
the case for the association between cannabis and psychosis and remains an 
ongoing area of controversy(Hill 2015; Gage et al. 2016). 
 
There is now a growing body of evidence to suggest that psychotic-like 
experiences with cannabis use, such as have been measured in this study, 
may act as a tractable marker for identifying those at putative psychotic risk. 
In an independent study patients with psychotic illness have been shown to 
experience more profound cannabis effects compared to Healthy Controls 
(HCs)(Bianconi et al. 2016). Administration of Delta-9-tetrahydrocannabinol 
(THC), the major psychotomimetic constituent of cannabis, has been 
demonstrated to elicit an increased psychotomimetic response in individuals 
with a psychotic illness as compared to HCs(D’Souza et al. 2005). 
!Furthermore increased schizotypy, a marker of psychosis-proneness, predicts 
increased psychotic-like experiences in cannabis users(Barkus et al. 2006). A 
large patient-sibling and sibling-control design study has demonstrated 
increased sensitivity of sub-threshold psychotic experiences to cannabis use 
amongst sibling-pairs of patients with psychosis as compared to 
controls(Kahn et al. 2011). Controlled experimental studies have 
demonstrated that variations in genes implicated in psychosis such as COMT, 
AKT1 and DAT1 may moderate greater sensitivity to the psychotomimetic 
effects of cannabis and its neurophysiological underpinnings in non-clinical 
populations(Henquet et al. 2006; Bhattacharyya et al. 2012). Taken together, 
increased sensitivity to cannabis-induced psychotomimetic experiences have 
been found in (i) patients with psychosis (ii) those with psychosis proneness 
and (iii) those with family history and genetic liability to psychosis, as 
compared to the general population. Thus the CEQ psychotic-like experiences 
score, as measured in this study, may give an indication of psychosis risk, 
although prospectively designed studies would be required to absolutely 
quantify this. 
 
If individuals with cannabis-induced psychotic-like experiences (who are at a 
putatively higher risk of developing disorder) were to discontinue use, as our 
results suggest, this may off-set the greater risk of developing psychotic 
disorder associated with cannabis use. We suggest that this might in turn 
explain the relative stability of rates of psychotic disorder over time despite the 
growing use of more potent forms of cannabis. Hence, we posit a 
discontinuation hypothesis leading to those at the highest risk of cannabis-
induced psychosis self-selecting themselves out of continued use and hence 
!protecting themselves from the risk of developing enduring psychotic 
disorders.  
 
Such an explanation is consistent with evidence that those at clinically high-
risk of psychosis discontinue cannabis use once breakthrough psychotic 
symptoms appear(Valmaggia et al. 2014) and independent evidence in the 
general population that subthreshold psychotic experiences, measured using 
the Community Assessment of Psychic Experience (CAPE) questionnaire (as 
distinct from cannabis induced psychotic-like experiences) predict cessation 
of cannabis use over six months to five years(van Gastel et al. 2014). 
 
These results are to be considered in light of certain limitations: the outcome 
measure reported self-reported continued use (yes/no) may vary or wane over 
time. However our findings remained in the same direction when we restricted 
the discontinued group to those who reported last use at least six months 
previously. Further the cross-sectional nature of our study precludes 
conclusions regarding the precise nature of these relationships. Nevertheless, 
the associations reported survived adjustment for multiple potential 
demographic and substance misuse confounders and were consistent across 
two different outcome measures. Arguably, the pragmatic design that we have 
employed using a convenience sample, rather than a probability sample also 
limits the generalizability of these results. While this would have been 
expected to result in under-reporting of psychotic-like symptoms associated 
with cannabis use as our sample was drawn from advertisements on social 
media and cannabis campaigning platforms, this did not occur, with around 
40% of the sample acknowledging they have either felt suspicious or nervy at 
some point from cannabis use. Arguably, the online data acquisition design 
!accorded anonymity allowing for more honest engagement with the survey as 
evident from the abundant qualitative data. Of note, a higher proportion of our 
sample (38.1%) reported a lifetime history of mental health contact than would 
be expected in the general population. Although we adjusted for mental health 
contact in our data, this did not include substance misuse treatment, which 
maybe seen as a limitation. Further we cannot completely exclude response 
bias or recall bias: those who have discontinued are likely to have used 
cannabis in the more distant past than those who continue use, and those 
who discontinue may be more likely to highly rate negative experiences. 
However, these biases are unlikely to have systematically affected the results 
as negative experiences are also rated similarly in those who continue to use 
but intend to quit in future.  
 
Finally, one must also consider the items used and the construct validity of the 
Cannabis Experiences Questionnaire for the experiences used and the 
sample studied. Principal Component Analysis of 55 different experiences (43 
immediate, 12 after-effects) in a previous British non-clinical cohort using an 
electronic survey has demonstrated the nine experiences we administered to 
load significantly with factor loading >0.5 onto their respective subscales 
(psychotic-like experiences and pleasurable effects)(Barkus & Lewis 2008). A 
further analysis of all the original experiences showed the nine experiences 
we administered to load similarly onto distinct subscales with factor >0.5 in 
the same manner, except for visual hallucinations which were not part of the 
solution(Stirling et al. 2008). A two-factor model for immediate experiences 
has recently been confirmed in independent non-clinical populations although 
notably auditory and visual hallucinations were not part of the final 13 item 
solution(Quinn et al. 2016). However, this latent structure has not been 
!universally validated in clinical populations: in a recent US sample in a first 
episode clinical population (n=194), Exploratory Factor Analysis using the 
original experiences identified four subscales amongst patients: distortions of 
reality and self-perception; euphoria effects; slowing and amotivational 
effects; and anxiety and paranoia effects(Birnbaum et al. 2017). This is 
similar, although not identical to another study involving both first episode 
patients and controls (patients n=252; controls n=207) where a four factor 
model was derived from 14 experiences namely: anxiety-paranoid 
experiences; cognitive experiences; enjoyable experiences and psychotic 
experiences(Bianconi et al. 2016). One explanation for this could be that 
cannabis experiences maybe differentially experienced in clinical and non-
clinical populations as suggested by the authors of both studies(Bianconi et 
al. 2016; Birnbaum et al. 2017), hence our results in a non-clinical sample 
cannot be generalized to patient groups which would need to be studied 
separately. 
 
Notwithstanding these limitations, using a well-validated measure which has 
now been used across multiple non-clinical populations(Barkus et al. 2006; 
Barkus & Lewis 2008; Stirling et al. 2008; Quinn et al. 2016) and a mixed-
methods approach, we report converging evidence from quantitative analysis 
controlling for potential confounders and independent qualitative analysis that 
psychotic-like experiences may predict cannabis cessation whereas 
pleasurable experiences may predict continued use as well as quantitative 
evidence that such experiences may also predict future intention to quit or 
continue cannabis use. 
 
!Together, these findings may suggest that psychotic-like experiences 
associated with cannabis use may have a protective effect on the risk of 
subsequent psychotic disorder by influencing future and continued cannabis 
use behaviour, and may go some way to explaining relative stability of rates of 
psychotic disorder over time. Prospective longitudinal studies are needed to 
definitively confirm or refute this possibility. 
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Table 1: Demographic data 
   
 
   
 
 
     
 
   
 
 
  
All 
(n=1231) 
Ceased 
(n=305) 
Continue
d (n=926) 
Sig.* Sig 
(msng
)†  
Intentio
n to 
Quit 
(n=166) 
No 
Intention 
to Quit 
(n=741) 
Sig.* Sig 
(msng)† 
Age x̄=29.5, 
sem=0.31 
x̄=29.5, 
sem=0.57 
x̄=29.5, 
sem=0.36 0.97   
x̄=25.1,           
sem=0.61 
x̄=30.4,             
sem=0.41 <0.01   
  Missing 102 (8.3) 27 (8.9) 75 (8.1)  0.72 15 (9.0) 58 (7.8)  0.64 
Sex Male 845 (68.6) 122 (40.0) 723 (78.1) 
<0.01   
117 (70.5) 592 (79.9) 
<0.01   
Female 375 (30.5) 182 (59.7) 193 (20.8)   48 (28.9) 140 (18.9)   
Missing 11 (0.9) 1 (0.3) 10 (1.1)  0.31 1 (0.6) 9 (1.2)  0.70 
Occupatio
n 
Full time 600 (48.9) 137 (44.9) 463 (50) 
<0.01 
  71 (42.8) 384 (51.8) 
<0.01 
  
Part time 109 (8.9) 25 (8.2) 84 (9.1)   14 (8.4) 69 (9.3)   
Unemployed 107 (8.9) 12 (3.9) 95 (10.3)   12 (7.2) 82 (11.1)   
Student 369 (30.0) 128 (42.0) 241 (26.0)   66 (39.8) 168 (22.7)   
Missing 46 (3.8) 3 (1.0) 43 (4.6)  0.03 3 (1.8) 38 (5.1)  0.06 
Mental 
Health 
contact 
Yes 469 (38.1) 133 (43.6) 336 (36.3) 
0.39 
  55 (33.1) 273 (36.8) 
0.37 
  
No 762 (61.9) 172 (56.4) 590 (63.7) 
  
111 (66.9) 468 (63.1) 
  
Age at first  
cbs use 
x̄=16.7, 
sem=0.11 
x̄=17.5, 
sem=0.18 
x̄=16.4, 
sem=0.13 <0.01   
x̄=16.2,           
sem=0.24 
x̄=16.5,           
sem=0.14 0.50   
  Missing 4 (0.3) 1 (0.3) 3 (0.3)  1.00 1 (0.6) 2 (0.3)  0.46 
Cbs 
frequency 
of use 
Every day 547 (44.4) 43 (14.1) 504 (54.4) 
<0.01 
  87 (52.4) 417 (56.2) 
0.49 
  
> once week 271 (22.0) 36 (11.8) 235 (25.4)   40 (24.1) 195 (26.3)   
Few times 
monthly 162 (13.2) 55 (18.0) 107 (11.6)   
24 (14.5) 83 (11.2) 
  
Few times yearly 132 (10.7) 84 (27.5) 48 (5.2)   10 (6.0) 38 (5.1)   
Once or twice 69 (5.6) 65 (21.3) 4 (0.4)   2 (1.2) 2 (0.3)   
Missing 50 (4.1) 22 (7.2) 28 (3.0)  <0.01 3 (1.8) 6 (0.8)  0.22 
Alcohol 
history 
Regular use 717 (58.2) 214 (70.2) 503 (54.3)    92 (55.4) 411 (55.5) 
0.34 
  
Infrequent use 323 (26.2) 46 (15.1) 277 (29.9) <0.01   52 (31.3) 225 (30.4)   
Use <5 times 31 (2.5) 2 (0.7) 29 (3.1)    3 (1.8) 26 (3.5)   
Never use 23 (1.9) 3 (1.0) 20 (2.2)    2 (1.2) 18 (2.4)   
Missing 137 (11.1) 40 (13.1) 97 (10.5)  0.21 17 (10.2) 61 (8.2)  0.44 
Tobacco 
history 
Regular use 633 (51.4) 113 (37.1) 520 (56.2) 
<0.01 
  102 (61.5) 418 (56.4) 
<0.01 
  
Infrequent use 256 (20.8) 78 (25.6) 178 (19.2)   33 (19.9) 145 (19.6)   
Use <5 times 125 (10.1) 42 (13.8) 83 (9.0)   11 (6.6) 72 (9.7)   
Never use 80 (6.5) 32 (10.5) 48 (5.1)   3 (1.8) 45 (6.1)   
Missing 137 (11.1) 40 (13.1) 97 (10.5)  0.21 17 (10.2) 61 (8.2)  0.44 
Non-
prescribed 
med 
history 
Regular use 53 (4.3) 8 (2.6) 45 (4.9) 
0.28 
  9 (5.4) 36 (4.9) 
0.76 
  
Infrequent use 163 (13.2) 35 (11.5) 128 (13.8)   19 (11.5) 109 (14.7)   
Use <5 times 224 (18.2) 54 (17.7) 170 (18.4)   30 (18.1) 140 (18.9)   
Never use 654 (53.1) 168 (55.1) 486 (52.5)   91 (54.8) 395 (53.3)   
Missing 137 (11.1) 40 (13.1) 97 (10.5)  0.21 17 (10.2) 61 (8.2)  0.44 
Cocaine 
history 
Regular use 75 (6.1) 11 (3.6) 64 (6.9) 
<0.01 
  12 (7.2) 52 (7.0) 
0.99 
  
Infrequent use 252 (20.5) 40 (13.1) 212 (22.9)   37 (22.3) 175 (23.6)   
Use <5 times 302 (24.5) 67 (22.0)  235 (25.4)   42 (25.3) 193 (26.0)   
Never use 465 (37.8) 147 (48.2) 318 (34.3)   58 (34.9) 260 (35.1)   
Missing 137 (11.1) 40 (13.1) 97 (10.5)  0.21 17 (10.2) 61 (8.2)  0.44 
Ecstasy 
history 
Regular use 136 (11.1) 26 (8.5) 110 (11.9) 
<0.01 
  18 (10.8) 92 (12.4) 
0.53 
  
Infrequent use 300 (24.4) 55 (18.0) 245 (26.5)   50 (30.1) 195 (26.3)   
Use <5 times 252 (20.5) 51 (16.7) 201 (21.7)   38 (22.9) 163 (22.0)   
Never use 406 (33.0) 133 (43.6) 273 (29.5)   43 (25.9) 230 (31.0)   
Missing 137 (11.1) 40 (13.1) 97 (10.5)  0.21 17 (10.2) 61 (8.2)  0.44 
     
 
   
 
 
! 
Legend: All data count (%ge) unless specified otherwise; x̄: mean; sem: standard error of the 
mean; cbs: cannabis; *Significance using t-tests for continuous variables, χ2 tests for 
proportions (infrequent categories combined if count<5) †Significance for missing data - 
Fisher’s exact test 2x2 contingency test 
  
 
 
 
 
   
 
  
 
!Table 2a: Cannabis Experiences mean scores by group: Discontinuation 
vs Continuation  
 
 Ceased Users  Continued Users  t-statistic  
and p-value† 
 Male Female All  Male Female All 
Psychotic-like 
Experiences 
9.93 
(0.44) 
n=102 
10.04 
(0.36) 
n=157 
10.02 
(0.28) 
n=260 
7.90 
(0.09) 
n=657 
8.24 
(0.23) 
n=172 
7.98 
(0.08) 
n=839 
t=7.05 
p<0.001 
Pleasurable 
Experiences 
8.97 
(0.32) 
n=103 
7.42 
(0.27) 
n=162 
8.02 
(0.21) 
n=266 
11.91 
(0.08) 
n=663 
11.28 
(0.20) 
n=174 
11.78 
(0.08) 
n=847 
t=-16.67 
p<0.001 
 
Legend: Psychotic-like Experiences: CEQ Score Psychotic-like Experiences; Pleasurable 
Experiences: CEQ Score Pleasurable/Pleasurable Experiences In boxes: Mean score (SEM) 
number in group 
† Independent samples t-test for cessation vs continuation. Positive t-statistic in direction of 
cessation. 
!Table 2b: Cannabis Experiences mean scores by group in Continued 
Users: Future intention to quit vs No future intention to quit 
 
 Future intention to quit  No intention to quit t-statistic  
and p-value† 
 Male Female All  Male Female All 
Psychotic-like 
Experiences 
8.74 
(0.30) 
n=102 
9.27 
(0.54) 
n=45 
8.88 
(0.27) 
n=148 
7.75 
(0.09) 
n=555 
7.88 (0.25) 
n=127 
7.78 
(0.08) 
n=691 
t=3.95 
p<0.001 
Pleasurable 
Experiences 
11.40 
(0.22) 
n=104 
11.30 
(0.39) 
n=46 
11.38 
(0.19) 
n=151 
12.01 
(0.09) 
n=559 
11.27 
(0.24) 
n=128 
11.86 
(0.08) 
n=696 
t=-2.37 
p=0.018 
 
Legend: Psychotic-like Experiences: CEQ Score Psychotic-like Experiences; Pleasurable 
Experiences: CEQ Score Pleasurable/Pleasurable Experiences In boxes: Mean score (SEM) 
number in group 
† Independent samples t-test for Future intention to quit vs. No future intention to quit. Positive 
t-statistic in direction of future intention to quit. 
 
 
!Table 3a: Logistic Regression for Cannabis 
Discontinuation/Continuation by co-variate 
 
  B S.E. Sig. Exp(B) 
95% C.I.for EXP(B) 
Lower Upper 
Psychotic-like 
Experiences 
0.233 0.035 <0.001 1.262 1.179 1.351 
Pleasurable 
Experiences 
-0.333 0.041 <0.001 0.717 0.662 0.776 
Age 0.049 0.012 <0.001 1.050 1.026 1.075 
Sex 0.593 0.233 0.011 1.809 1.146 2.856 
Occupation -0.003 0.086 0.974 0.997 0.842 1.181 
Mental Health Contact -0.347 0.229 0.130 0.707 0.451 1.108 
Age of first cannabis 
use 
-0.015 0.034 0.651 0.985 0.922 1.052 
Frequency of cannabis 
use 
0.824 0.104 <0.001 2.279 1.859 2.795 
Alcohol history -0.225 0.207 0.276 0.798 0.532 1.197 
Tobacco history 0.235 0.121 
0.051 
1.265 0.999 1.603 
Non prescribed 
medications history 
0.055 0.137 0.686 1.057 0.808 1.382 
Cocaine history 0.276 0.165 0.094 1.318 0.954 1.820 
Ecstasy history 0.006 0.137 0.962 1.006 0.769 1.317 
Constant -4.371 1.202 <0.001 0.013     
 
Legend: Psychotic-like Experiences: CEQ Score Psychotic-like Experiences; Pleasurable 
Experiences: CEQ Score Pleasurable/Pleasurable Experiences. Positive Bs in direction of 
cessation. 
!Table 3b: Logistic Regression for Future intention to quit / No intention 
to quit by co-variate 
 
  B S.E. Sig. Exp(B) 
95% C.I.for EXP(B) 
Lower Upper 
Psychotic-like 
Experiences 0.123 0.040 0.003 1.131 1.044 1.225 
Pleasurable Experiences -0.114 00.047 0.015 0.892 0.814 0.978 
Age -0.075 0.016 <0.001 0.927 0.898 0.958 
Sex 0.737 0.248 0.003 2.090 1.282 3.408 
Occupation -0.059 0.080 0.492 0.943 0.797 1.115 
Mental Health Contact 0.204 0.233 0.388 1.226 0.772 1.945 
Age of first cannabis use 0.054 0.037 0.150 1.056 0.981 1.136 
Frequency of cannabis use -0.006 0.118 0.957 0.994 0.789 1.252 
Alcohol history 0.178 0.172 0.308 1.195 0.848 1.682 
Tobacco history -0.453 0.143 0.002 0.635 0.479 0.842 
Non prescribed 
medications history 0.274 0.137 0.049 1.316 1.001 1.730 
Cocaine history -0.079 0.146 0.592 0.924 0.692 1.233 
Ecstasy history -0.002 0.130 0.988 0.998 0.771 1.293 
Constant -1.399 1.261 0.269 0.247 
   
Legend: Psychotic-like Experiences: CEQ Score Psychotic-like Experiences; Pleasurable 
Experiences: CEQ Score Pleasurable/Pleasurable Experiences. Positive Bs in direction of 
future intention to quit. 
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!Supplemental Data 
 
Complete Case Data 
 
This comprised 940 cases where complete data was available. 
 
Table 1a: Cannabis Experiences mean scores by group: Discontinued vs Continued Use 
 
 Ceased Users  Continued Users  t-statistic  
and p-value† 
 Male Female All  Male Femal
e 
All 
Psychotic-like 
Experiences 
9.83 
(0.43) 
n=95 
10.14 
(0.39) 
n=137 
10.01 
(0.29) 
n=232 
7.85 
(0.09) 
n=554 
8.40 
(0.25) 
n=154 
7.97 
(0.09) 
n=708 
t=6.72 
p<0.001 
 Pleasurable 
Experiences 
9.02 
(0.33) 
n=95 
7.37 
(0.29) 
n=137 
8.04 
(0.22) 
n=232 
11.94 
(0.09) 
n=554 
11.29 
(0.22) 
n=154 
11.80 
(0.09) 
n=708 
t=-15.62 
p<0.001 
 
Legend: Psychotic-like Experiences: CEQ Score Psychotic-like Experiences; Pleasurable Experiences: CEQ 
Score Pleasurable/Pleasurable Experiences In boxes: Mean score (SEM) number in group 
† Independent samples t-test for discontinuation vs continuation. Positive t-statistic in direction of discontinuation. 
 
________ 
 
Table 1b: Cannabis Experiences mean scores by group in Continued Users: Future 
intention to quit vs No future intention to quit 
 
 No intention to quit Future intention to quit t-statistic  
and p-value† 
 Male Female All  Male Female All 
Psychotic-like 
Experiences 
7.72 
(0.09) 
n=467 
8.05 
(0.28) 
n=110 
7.78 
(0.09) 
n=577 
8.57 
(0.32) 
n=87 
9.30 
(0.55) 
n=44 
8.82 
(0.28) 
n=131 
t=3.47 
p=0.001 
 Pleasurable 
Experiences 
12.03 
(0.09) 
n=467 
11.26 
(0.26) 
n=110 
11.89 
(0.09) 
n=577 
11.40 
(0.24) 
n=87 
11.36 
(0.40) 
n=44 
11.38 
(0.21) 
n=131 
t=-2.26 
p=0.024 
 
Legend: Psychotic-like Experiences: CEQ Score Psychotic-like Experiences; Pleasurable Experiences: CEQ 
Score Pleasurable/Pleasurable Experiences In boxes: Mean score (SEM) number in group 
† Independent samples t-test for Future intention to quit vs. No future intention to quit. Positive t-statistic in direction 
of future intention to quit. 
 
 
!Complete Case Data with those with history of psychosis or manic illness removed 
 
This comprised 915 cases. 
 
Table 2a: Cannabis Experiences mean scores by group: Discontinued vs Continued Use 
 
 Ceased Users  Continued Users  t-statistic  
and p-value† 
 Male Female All  Male Female All 
Psychotic-like 
Experiences 
9.79 
(0.43) 
n=92 
10.05 
(0.39) 
n=131 
10.01 
(0.29) 
n=223 
7.84 
(0.09) 
n=544 
8.41 
(0.26) 
n=148 
7.96 
(0.09) 
n=692 
t=6.48 
p<0.001 
Pleasurable 
Experiences 
9.04 
(0.34) 
n=92 
7.44 
(0.30) 
n=131 
8.04 
(0.22) 
n=223 
11.91 
(0.09) 
n=544 
11.26 
(0.23) 
n=148 
11.77 
(0.09) 
n=692 
t=-14.94 
p<0.001 
 
Legend: Psychotic-like Experiences: CEQ Score Psychotic-like Experiences; Pleasurable Experiences: CEQ 
Score Pleasurable/Pleasurable Experiences In boxes: Mean score (SEM) number in group 
† Independent samples t-test for discontinuation vs continuation. Positive t-statistic in direction of discontinuation. 
 
________ 
 
Table 2b: Cannabis Experiences mean scores by group in Continued Users: Future 
intention to quit vs No future intention to quit 
 
 No intention to quit Future intention to quit t-statistic  
and p-value† 
 Male Female All  Male Female All 
Psychotic-like 
Experiences 
7.70 
(0.09) 
n=458 
8.08 
(0.29) 
n=106 
7.77 
(0.09) 
n=564 
8.58 
(0.33) 
n=86 
9.30 
(0.57) 
n=42 
8.80 
(0.29) 
n=128 
t=3.42 
p=0.001 
 Pleasurable 
Experiences 
12.02 
(0.10) 
n=458 
11.22 
(0.27) 
n=106 
11.87 
(0.10) 
n=564 
11.36 
(0.24) 
n=86 
11.36 
(0.42) 
n=42 
11.36 
(0.21) 
n=128 
t=-2.27 
p=0.024 
 
Legend: Psychotic-like Experiences: CEQ Score Psychotic-like Experiences; Pleasurable Experiences: CEQ 
Score Pleasurable/Pleasurable Experiences In boxes: Mean score (SEM) number in group 
† Independent samples t-test for Future intention to quit vs. No future intention to quit. Positive t-statistic in direction 
of future intention to quit. 
!Table 3a: Logistic Regression for Cannabis Discontinuation/Continuation by co-variate 
for Complete Case Data with those with history of psychosis or manic illness removed 
 
  B S.E. Sig. Exp(B) 
95% C.I.for EXP(B) 
Lower Upper 
Psychotic-like 
Experiences 0.235 0.035 <0.001 1.265 1.180 1.356 
Pleasurable 
Experiences -0.318 0.041 <0.001 0.727 0.671 0.789 
Age 0.049 0.012 <0.001 1.050 1.025 1.076 
Sex 0.587 0.236 0.013 1.799 1.133 2.857 
Occupation -0.013 0.088 0.879 0.987 0.831 1.172 
Mental Health Contact -0.317 0.232 0.173 0.728 0.462 1.149 
Age of first cannabis 
use -0.012 0.034 0.731 0.988 0.925 1.056 
Frequency of cannabis 
use 0.857 0.107 <0.001 2.356 1.909 2.908 
Alcohol history -0.247 0.211 0.241 0.781 0.516 1.181 
Tobacco history 
0.199 0.122 0.104 1.220 0.960 1.550 
Non prescribed 
medications history 0.048 0.139 0.730 1.049 0.798 1.379 
Cocaine history 0.287 0.168 0.087 1.333 0.960 1.851 
Ecstasy history 0.011 0.139 0.938 1.011 0.770 1.326 
Constant -4.636 1.229 <0.001 0.010 - - 
 
Legend: Psychotic-like Experiences: CEQ Score Psychotic-like Experiences; Pleasurable Experiences: CEQ 
Score Pleasurable/Pleasurable Experiences. Positive Bs in direction of discontinuation. 
 
Table 3b: Logistic Regression for Future intention to quit / No intention to quit by co-
variate for Complete Case Data with those with history of psychosis or manic illness 
removed 
 
  B S.E. Sig. Exp(B) 
95% C.I.for EXP(B) 
Lower Upper 
Psychotic-like 
Experiences 0.128 0.041 0.002 1.136 1.233 1.048 
Pleasurable Experiences -0.118 0.047 0.012 0.888 0.975 0.810 
Age -0.073 0.017 <0.001 0.929 0.961 0.899 
Sex 0.729 0.255 0.004 2.075 3.425 1.258 
Occupation -0.059 0.087 0.497 0.943 1.119 0.794 
Mental Health Contact 0.204 0.239 0.394 1.225 1.961 0.767 
Age of first cannabis use 0.060 0.037 0.106 1.063 1.143 0.987 
Frequency of cannabis use -0.019 0.121 0.875 0.981 1.242 0.775 
Alcohol history 0.153 0.177 0.386 1.166 1.647 0.824 
Tobacco history -0.461 0.144 0.001 0.631 0.837 0.475 
Non prescribed 
medications history 0.318 0.144 0.027 1.374 1.821 1.036 
Cocaine history -0.041 0.149 0.785 0.960 1.285 0.717 
Ecstasy history -0.013 0.133 0.923 0.987 1.282 0.760 
Constant -1.706 1.284 0.184 0.182 - - 
 
Legend: Psychotic-like Experiences: CEQ Score Psychotic-like Experiences; Pleasurable Experiences: CEQ 
Score Pleasurable/Pleasurable Experiences. Positive Bs in direction of future intention to quit. 
!Complete Case Data with discontinued groups restricted to those who have discontinued for 6 
months or more 
 
This comprised 785 cases. 
 
Table 4: Cannabis Experiences mean scores by group: Discontinued (specified more 
than 6 months) vs Continued Use 
 
 Ceased Users  Continued Users  t-statistic  
and p-value† 
 Male Female All  Male Female All 
Psychotic-like 
Experiences 
11.08 
(0.81) 
n=37 
10.73 
(0.78) 
n=40 
10.01 
(0.29) 
n=223 
7.85 
(0.09) 
n=554 
8.40 
(0.25) 
n=154 
7.97 
(0.09) 
n=708 
t=5.15 
p<0.001 
Pleasurable 
Experiences 
9.84 
(0.51) 
n=37 
8.20 
(0.55) 
n=40 
8.04 
(0.22) 
n=223 
11.94 
(0.09) 
n=554 
11.29 
(0.22) 
n=154 
11.80 
(0.09) 
n=708 
t=-7.09 
p<0.001 
 
Legend: Psychotic-like Experiences: CEQ Score Psychotic-like Experiences; Pleasurable Experiences: CEQ 
Score Pleasurable/Pleasurable Experiences In boxes: Mean score (SEM) number in group 
† Independent samples t-test for discontinuation vs continuation. Positive t-statistic in direction of discontinuation. 
 
Table 5: Logistic Regression for Cannabis Discontinuation/Continuation by co-variate for 
Complete Case Data with discontinued users restricted to those who specified last use 
more than 6 months prior 
 
  B S.E. Sig. Exp(B) 
95% C.I.for EXP(B) 
Lower Upper 
Psychotic-like 
Experiences 0.249 0.044 <0.001 1.282 1.175 1.399 
Pleasurable 
Experiences -0.271 0.056 <0.001 0.762 0.683 0.851 
Age 0.033 0.016 0.039 1.034 1.002 1.067 
Sex 0.357 0.330 0.279 1.429 0.749 2.727 
Occupation 0.002 0.119 0.989 1.002 0.793 1.264 
Mental Health Contact -0.456 0.329 0.165 0.634 0.333 1.207 
Age of first cannabis 
use -0.022 0.051 0.664 0.978 0.884 1.081 
Frequency of cannabis 
use 0.713 0.141 <0.001 2.041 1.549 2.688 
Alcohol history -0.307 0.309 0.320 0.736 0.402 1.347 
Tobacco history 
0.126 0.167 0.448 1.135 0.819 1.573 
Non prescribed 
medications history 0.241 0.206 0.241 1.273 0.850 1.905 
Cocaine history 0.202 0.227 0.374 1.224 0.784 1.912 
Ecstasy history 0.267 0.192 0.163 1.307 0.897 1.903 
Constant -5.682 1.791 0.002 0.003 - - 
 
Legend: Psychotic-like Experiences: CEQ Score Psychotic-like Experiences; Pleasurable Experiences: CEQ 
Score Pleasurable/Pleasurable Experiences. Positive Bs in direction of discontinuation. 
 
 
!Table 6: Logistic Regression for Cannabis Discontinuation/Continuation and Future intention to 
quit / No intention to quit for Complete Case Data by frequency of use 
 
 
 
 
Discontinuation vs continuation Future Intention to quit vs no intention 
 
n 
Psychotic 
Like 
Experiences 
p-
value 
Pleasurable 
experiences 
p-
value n 
Psychotic 
Like 
Experiences 
p-
value 
Pleasurable 
experiences 
 p-
value 
Daily Use 427 1.328 <0.001 0.731 <0.001 393 1.156 0.016 0.82 0.004 
More than 
once 
weekly 224 1.571 <0.001 0.532 <0.001 190 1.043 0.643 0.922 0.464 
A few times 
each month 129 1.225 0.02 0.805 0.026 82 1.091 0.558 0.906 0.447 
A few times 
each year 104 1.177 0.059 0.699 <0.001 39 Not calculated as numbers too small 
Only once 
or twice 56 0.965 0.923 0.368 0.528 4 Not calculated as numbers too small 
 
 
 
Legend: Psychotic-like Experiences: CEQ Score Psychotic-like Experiences; Pleasurable Experiences: CEQ Score 
Pleasurable/Pleasurable Experiences. Numbers in columns are Exp(B) (adjusted Odds Ratios) from Logistic Regression. 
Exp(B)>1 in direction of discontinuation/future intention to quit. 
!Qualitative data:* 
 
<‘Why did you stop?’> 
Coding Report for dominant code – ‘Negative psychological symptoms’ 
 
Reference 1  
 
Started feeling negative symptoms such as paranoia and loss of control over thoughts. 
 
Reference 2  
 
Using cannabis increased my feelings of depression and anxiety for a period of time after 
ingestion. I decided to stop using cannabis when the feelings of depression and anxiety that its 
use stimulated outweighed the enjoyment I experienced from cannabis use. 
 
Reference 3  
 
Panic attacks and other anxiety symptoms. Relative with mental illness relating to drug use 
 
Reference 4  
 
negative effects on mood and productivity 
 
Reference 5  
 
I didn't like it. Because I knew it was illegal, it made me feel a heightened sense of paranoia 
almost every time. It wasn't worth it after a while. 
 
Reference 6  
 
I tended to binge and realised this was unhelpful in terms of my mood and mental stability. 
 
Reference 7  
 
I did not like the experience whenever I used it 
 
Reference 8  
 
made me paranoid and unhappy 
 
Reference 9  
 
Just haven't used it in a while, but might use it again, when there is a chance. My last 
experiences with it seemed make me rather anxious for a while, and then relaxed me. 
 
Reference 10  
 
It is an awful drug, it completely effected my entire perceptions such that I felt the effect for more 
than two weeks. 
 
Reference 11  
 
paranoia 
 !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!* Using participants’ original spelling and grammar 
!Reference 12  
 
I didn't enjoy the feeling of having less control 
 
Reference 13  
 
My reactions grew worse and worse, at times vomiting, anxiety, etc. Although in the end I 
smoked very rarely and very little and could enjoy it, my previous experiences scarred me. 
 
Reference 14  
 
Only used very infrequently and don't use now because I don't enjoy it and don't want it to 
negatively affect my mental health. 
 
Reference 15  
 
Cannabis in England seemed stronger than back home and made me feel more anxious. I also 
used to smoke a lot of hash and I could not find a good hash source in England. 
 
Reference 16  
 
Affected academic performance, caused paranoia, also against religous beliefs. 
 
Reference 17  
 
Started getting anxiety attacks when going through menopause 
 
Reference 18  
 
difficult life experiences led to too much rumination with cannabis, leading to paranoia! 
 
Reference 19  
 
Smoked variety of very strong cannabis over the course of a weekend and felt anxious and 
mildly paranoid for a day or do afterwards 
 
Reference 20  
 
I didn't like the effect it had on me. Made me quite paranoid and just didn't enjoy the effect on 
me. 
 
Reference 21  
 
The cannabis I was able to get, was presumably skunk, and it made me extremely anxious and 
paranoid. In the past I took other varieties that could be quite pleasant.   The Paranoid thought 
patterns are very unpleasent. I was also worried about my family history of schizophrenia, my 
bipolar disorder and potential drug interactions. 
 
Reference 22  
 
I started to have medical problems as paranoia, anxiety or depression 
 
Reference 23  
 
When I got my first appointment at a psychiatric clinic, I decided to quit. I had always told myself 
that I would take an eventual psychiatric treatment seriously and not smoking pot during it 
!seemed like a no brainer... 
 
Reference 24  
 
It stopped giving me new ideas and good vibes. I just got ""stoned"" and then it wasn't any fun. 
 
Reference 25  
 
does not have a good effect on me- feeling of tiredness, difficulty to concentrate, slight feelings 
of anxiety, irritable 
 
Reference 26  
 
It started to make me feel anxious 
 
Reference 27  
 
I wasn't enjoying it anymore. It had started to have an adverse effect on my mood. 
 
Reference 28  
 
Enjoyed feeling less and less. Became anxious and slightly paranoid and then had a 3 month 
extreme psychotic episode which stopped after I stopped smoking cannabis. 
 
Reference 29  
 
paranoia and 'busy head' couldn;t sleep 
 
Reference 30  
 
caused paranoia. 
 
Reference 31  
 
It made me very anxious and paranoid. Also interfered with homework and school. 
 
Reference 32  
 
Started making me feel uncomfortable and anxious 
 
Reference 33  
 
was making me feel low, concerns about lung health risks, worked with children 
 
Reference 34  
 
It made me feel anxious in social situations, i got completely list in my own thoughts. Paranoia 
 
Reference 35  
 
hated the smell and the high made me feel paranoid and sluggish 
 
Reference 36  
 
Had the episode of submission and then onwards was advised not to use again 
 
!Reference 37  
 
Made me anxious 
 
Reference 38  
 
I smoked it daily when I was a teenager, then as I got older I mostly used it after/during using 
different drugs.  I grew to dislike it more as time went on because it made me anxious, paranoid, 
difficultly sleeping and led me to over think things a lot. 
 
Reference 39  
 
I only enjoyed it in a certain group of people. Normally when on a comedown from MDMA. 
Didn't enjoy it too much made me paranoid. Ruined the buzz from the other drug. 
 
Reference 40  
 
It made me feel anxious and paranoid 
 
Reference 41  
 
It became not a fun experience any more, became paranoid both when using it and when not 
using and started having negative reactions to it too regularly 
 
Reference 42  
 
It was the right thing to do, health wise. I was having mental issues, and one day I decided to 
stop and haven't ever since. 
 
Reference 43  
 
Paranoia 
 
Reference 44  
 
it made me too forgetful, it interfered with my daily routines. I stopped paying attention to the 
world around me. 
 
Reference 45  
 
Experienced only adverse effects - could not concentrate 
 
Reference 46  
 
Had a paranoid reaction one time 
! 
< If your pattern of use has changed over time why> 
Coding report for dominant code ‘negative effects’ 
 
Reference 1  
 
It stopped feeling good and the effects I had did not seem to affect my friends. 
 
Reference 2  
 
peaked during undergraduate degree, stopped due to negative effects 
 
Reference 3  
 
it was fun at first but then rather than get giggly it made me very paranoid and withdrawn both 
during smoking and in the weeks after, so I stopped completely. 
 
Reference 4  
 
Hard to wake up in the morning for work after smoking 
 
Reference 5 
 
stopped - paramoia 
 
Reference 6 
 
From 19-23 I smoked daily, after low moods and anxiety/panic attack I completely stopped and 
have been smoking again 2-3 times a week for the past few months 
 
Reference 7  
 
at first it was a novel thhing, exciting, like having alcohol for the first time in social settings. The 
people that had it aged 17 seemed cool. However as I grew up and left sixth form I realised I 
didnt enjoy it that much, I saw the negative effects of it during my gap year and began saying no 
until my friendship group changed etc. I dont miss it to be honest 
 
Reference 8 
 
After about a year of smoking somewhat regularly I had a very bad reaction which threw me off. 
Smoked half a joint at a club, started throwing up, felt very dizzy, had to be picked up. The weed 
came from a person I knew quite well, he did not have these reactions. 
 
Reference 9  
 
After a few years of every week (sometimes every day) usage I realized that I was spending too 
much time for nothing. Also, I had a few episodes of panic attack and it was correlated with high 
usage. Additionally, every day usage makes you lazy, weak, unconcentrated etc. 
 
Reference 10  
 
tried it a few times on and off with friends, didn't really get or understand the effects of it other 
than it made me feel dizzy, so stopped doing it 
 
Reference 11  
 
!When I was younger I had easy access to it and it was my preferred drug of choice so I used it a 
lot ( 4-5 a week). It was also social consumption where evenings were spent with friends 
watching movies, smoking cannabis and just generally chilling. I started smoking less cannabis 
when i started going out more and using other drugs. I then stopped using cannabis when I 
found that it was getting too strong and only making me anxious. 
 
Reference 12 
 
Because of the panic attacks i am scared to try it again and I have no access to a safe supply.  
If it was legal I would grow my own and use it as plant medicine. 
 
Reference 13  
 
i did it a few times with friends but i disliked it 
 
Reference 14  
 
experimental use. suffered with nausea/vomiting 
 
Reference 15  
 
has got less- I smoked it when i was 14/15 but had a bad experience and havent smoked since 
 
Reference 16  
 
My intensity of use diminished gradually. For the last few years I was smoking 100mg or less. 
But a daily use pattern persisted. My job is in substance misuse so the tell tale signs around the 
eyes became a problem. My life became busier and more responsible and in the end I found the 
effects were unwanted, less pleasant and too long acting. As a father, the effect on sleep began 
to count - meaning I would feel tired in the morning even having smoked very small amounts. 
Also, my partner doesn't like the smell on my breath. 
 
Reference 17  
 
at the age of 18 I used to smoke almost everyday (my friends smoked everyday as well) but 
around 19 I started to have medical problems as paranoia, around 20 I started to go to the 
psychiatrist and I stopped smoking cannabis. 
 
Reference 18  
 
I stopped smoking because I moved to Korea. It also held me back generally from achieving 
what I wanted to do. It slowed me down cognitively and significantly decreased my affective 
states. 
 
Reference 19  
 
Between the ages of 19 and 24 I smoked it very heavily.  Between 24 and 33 I only smoked it 
sporadically due to pregnancy and breastfeeding.  By 34 I had stopped completely because I 
had children to look after and career ambitions.  Cannabis use was just a waste of my time and 
by that point I experienced extreme anxiety when smoking it. 
 
Reference 20  
 
It was helping my ADHD but killing my motivation, so I don't use it as much anymore 
 
Reference 21  
! 
Availability when I was younger like 16-19. And availability now Iam 21. Furthermore I don't do it 
much nowadays because it dumbs down my thinking and personally I don't like that . 
 
Reference 22  
 
caused severe paranoid episode aged 21 and stopped at this point. 
 
Reference 23  
 
I cannot handle the effects - I don't like feeling so anxious/paranoid 
 
Reference 24  
 
I stopped as I realised I didn't enjoy it, it made me paranoid and was a waste of money 
 
Reference 25  
 
Had unexpected physiological responses (e.g fainting, auditory sensitivity,overeating)  When 
paired with other abusive substances it resulted in negative emotional/psychological affects that 
were debilitating for me in my daily routine/life 
 
Reference 26  
 
found cannabis bad for mental health 
 
Reference 27  
 
It has increased due to traumatic life events 
 
Reference 28 
 
Don't use it hardly ever anymore cos I have a negative reaction to it so if I do it'll be like 1 or 2 
tokes which is usually okay but try not to 
! 
<Would you like to stop using cannabis one day>  
Coding report for exemplar code – ‘maturing out’ 
 
Reference 1  
 
I don't see myself using cannabis for the rest of my life. I am currently enjoying it, as a young 
person, but I do not depend on it and definitely will stop in the next few years. 
 
Reference 2  
 
Well i wouldn't see myself using cannabis when I've had children or when I get a full time job 
 
Reference 3  
 
I don't use it regularly but on occasion, I don't see myself using cannabis as I get older. 
 
Reference 4  
 
When I am older and have a family I will not be a frequent user of cannabis but I would not be 
opposed to engaging in the activity every so often. 
 
Reference 5  
 
I do not see cannabis as something which will be suited for every stage of my life. There will be 
a time where it would become irresponsible (e.g. when I have children etc) 
 
Reference 6 
 
Growing older may have to focus on other responsibilities 
 
Reference 7  
 
I don't see myself smoking when I have more work / family responsibility. 
 
Reference 8  
 
I'm believe I will stop some day, when I have matured more. Right now my current living 
situation and lift style can accommodate smoking cannabis, but someday that may change, like 
if I have children, get married, or get a more serious job. 
 
Reference 9  
 
Can't get stoned for the rest of my life 
 
Reference 10  
 
i don't intend to do anything forever. everything eventually gets boring, people change, life goes 
on. 
 
Reference 11  
 
In the future I'm likely to have responsibilities ( eg a career/family) that may mean I will not be 
able to use it 
 
Reference 12  
! 
Maybe not stop 100%. But definitely cut down a lot after uni and when/if I have children it won't 
be smoked around them. 
 
Reference 13  
 
Eventually as I get older and start getting a job, it'll be best to stop and just focus on my career 
 
Reference 14  
 
I've been smoking weed for the last 7 years, and I am still smoking, but I believe that you can't 
really smoke till the end of you life...don't know why. 
 
Reference 15  
 
It's not a forever sort of thing 
 
 
